Evolution of Aqueous Flare in Rhegmatogenous Retinal Detachments Treated With Gas or Silicone Oil Tamponade.
NCT ID: NCT05053698
Last Updated: 2021-09-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
48 participants
OBSERVATIONAL
2020-06-03
2021-06-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Group 1 : 48 eyes primarily treated with gas tamponade
* Group 2 : 11 eyes primarily treated with silicone oil tamponade
* Sub-Group G1RG : 8 eyes among Group 1 treated with gas after relapse
* Sub-Group G1RS : 3 eyes among Group 1 treated with silicone oil after relapse
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Retinal Redetachment After Silicone Oil Removal : a Risk Factor Analysis
NCT05647928
Internal Limiting Membrane Peeling in Retinal Detachment Surgery
NCT05538156
Primary Vitrectomy With Silicone Oil or SF6 for Rhegmatogenous Retinal Detachment
NCT05377606
Cystoid Macular Edema After Vitrectomy for Rhegmatogenous Retinal Detachment
NCT05069675
Primary Vitrectomy for the Treatment of Retinal Detachment in Highly Myopic
NCT01480505
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Initial gas tamponade
Primary vitrectomy and fluid-air exchange with SF6 or C2F6 gas tamponade
Aqueous flare measurement
Aqueous flare was measured preoperatively and postoperatively with a laser flare-cell meter (LFCM ; Kowa FM-500, Kowa Company Ltd, Tokyo, Japan).
Initial silicone oil tamponade
Primary vitrectomy and fluid-air exchange with silicone oil tamponade
Aqueous flare measurement
Aqueous flare was measured preoperatively and postoperatively with a laser flare-cell meter (LFCM ; Kowa FM-500, Kowa Company Ltd, Tokyo, Japan).
Relapse treated with gas tamponade
Secondary vitrectomy and fluid-air exchange with SF6 or C2F6 or C3F8 gas tamponade
Aqueous flare measurement
Aqueous flare was measured preoperatively and postoperatively with a laser flare-cell meter (LFCM ; Kowa FM-500, Kowa Company Ltd, Tokyo, Japan).
Relapse treated with silicone oil tamponade
Secondary vitrectomy and fluid-air exchange with silicone oil tamponade
Aqueous flare measurement
Aqueous flare was measured preoperatively and postoperatively with a laser flare-cell meter (LFCM ; Kowa FM-500, Kowa Company Ltd, Tokyo, Japan).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Aqueous flare measurement
Aqueous flare was measured preoperatively and postoperatively with a laser flare-cell meter (LFCM ; Kowa FM-500, Kowa Company Ltd, Tokyo, Japan).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patients who underwent surgery for rhegmatogenous retinal detachment (silicone or gas tamponade)
* aqueous flare measurement carried out preoperatively and postoperatively at 2-4 weeks and 3 months
Exclusion Criteria
* glaucoma
* non rhegmatogenous retinal detachment
* active uveitis
* pseudoexfoliation syndrome.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Central Hospital, Nancy, France
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
BERROD Jean-Paul
Professor BERROD Jean-Paul
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jean-Paul BERROD, Professor MD
Role: PRINCIPAL_INVESTIGATOR
Central Hospital, Nancy, France
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
BERROD Jean-Paul MD
Nancy, Grand Est, France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020PI209
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.